MetaCap

Intercure (INCR) vs Rallybio (RLYB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rallybio (RLYB) has outperformed Intercure (INCR) over the past year, gaining 208.4% versus a loss of 50.6%. Over five years, RLYB leads with a -85.3% price change compared with -90.9% for INCR. Rallybio is the larger company by market cap ($43.3 million vs $42.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INCR-50.57%RLYB+208.41%
+258%+96%-65%
Nov 21, 20251 yearNov 20, 2026
INCR-91.77%RLYB-85.73%
+13%-45%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INCR versus RLYB key metrics
MetricINCRRLYB
Share price$3.24$15.47
Market cap$42.03M$43.32M
1-day change-7.69%-0.32%
YTD return-28.79%+181.89%
1-year return-50.57%+208.41%
5-year return-90.87%-85.29%
P/E ratio (TTM)—3.36
EPS (TTM)$-0.95$4.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$858.00K
Revenue growth (YoY)—+34.91%
Net income (latest FY)—$-8.98M
Operating margin—-3853.61%
Net margin—-1046.39%
52-week high$7.55$35.15
52-week low$3.12$7.34
Distance from 52-week high-57.09%-55.99%
Average volume15.93K10.14K
Shares outstanding12.97M2.80M
Employees2857
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RLYB has outperformed INCR by 259.0 percentage points over the past year.

About Intercure

INCR stock →

InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.

Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees

About Rallybio

RLYB stock →

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

INCR vs RLYB FAQ

Which is bigger, Intercure or Rallybio?

Rallybio (RLYB) is larger, with a market capitalization of $43.32M compared with $42.03M for Intercure (INCR).

Which stock has performed better over the past year, INCR or RLYB?

RLYB returned +208.41% over the past 12 months, compared with -50.57% for INCR (price return, excluding dividends). Past performance does not predict future results.

Are Intercure and Rallybio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons